Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 357 clinical trials
A Study of Pyrotinib Plus Capecitabine Combined With SRT in HER2+ MBC With Brain Metastases

This study evaluates the efficacy and safety of SRT combined with pyrotinib and capecitabine in the treatment of patients with HER2-positive advanced breast cancer patients with brain metastases

  • 15 Mar, 2022
  • 1 location
Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study

The purpose of this study is to see if Cs-131 brachytherapy is effective in people with recurrent brain cancer who are scheduled to have brain surgery for removal of their tumor(s). The researchers would like to see whether Cs-131 prevents brain tumors from growing back after surgery.The researchers will compare …

  • 22 Dec, 2021
  • 5 locations
A Phase II Study of Pre-Op SRS Followed by Surgical Resection for Brain Metastases

This is a research study to determine if performing stereotactic radiosurgery (SRS) prior to surgical resection of the brain metastasis (tumor) will improve local control, in other words

  • 05 May, 2022
  • 1 location
A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases (OUTRUN)

20-40% of patients with NSCLC will develop brain metastases at some point during their course of disease. Osimertinib has demonstrated intracranial activity in EFGR mutated NSCLC with

  • 19 Feb, 2022
  • 10 locations
Stereotactic Radiotherapy for Cerebral Metastases With Recent Hemorrhagic Signal (STEREO-HBM)

This prospective 2-stage, non-randomized Phase 2 trial evaluates the safety and efficacy of FSRT for the management of hemorrhagic brain metastases

  • 08 Feb, 2022
  • 2 locations
Durvalumab and Low-dose PCI vs Durvalumab and Observation in Radically Treated Patients With Stage III NSCLC (NVALT28) (NVALT28)

This trial studies the combination of low-dose PCI with or without durvalumab in patients with radically treated stage III NSCLC. The hypothesis is that the incidence of brain metastases will be

cancer chemotherapy
lung carcinoma
brain metastases
  • 25 Mar, 2022
  • 4 locations
Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer

bevacizumab in the management of patients with brain metastasis harboring EGFR mutation.

growth factor
epidermal growth factor
lung carcinoma
measurable disease
  • 11 Nov, 2021
  • 1 location
Neurocognition in NSCLC Patients Treated With Osimertinib or Osimertinib + WBI

-mutant (Ex 19Del and L858R) NSCLC patients with symptomatic brain metastases, as well as the efficacy and safety.

  • 11 Apr, 2021
  • 1 location
Simulation-Free Hippocampal-Avoidance Whole Brain Radiotherapy Using Diagnostic MRI-Based and Cone Beam Computed Tomography-Guided On-Table Adaptive Planning in a Novel Ring Gantry Radiotherapy Device

. When used in addition to prophylactic memantine, this technique has been shown to better preserve cognitive function in patients with brain metastases outside of the hippocampal-avoidance region with

  • 23 Mar, 2022
  • 1 location
OMEGA, Local Ablative Therapy in Oligometastatic NSCLC (OMEGA)

> Disease state and life status will be assessed on a 3-monthly basis by physical examination, whole-body CT scan plus repeat PET-scan if needed and Brain MRI if brain metastasis at enrolment. Toxicity and

ct scan
cancer chemotherapy
platinum doublet
stage iv non-small cell lung cancer
  • 24 Feb, 2022
  • 1 location